Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.58 |
| ▸ | IKBKB | O14920 | 4/20 | 0.54 |
| ▸ | CHUK | O15111 | 4/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | PRKX | P51817 | 1/20 | 0.45 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239776 | 1.00 | HRH1 (0.58) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| SCHEMBL187501 | 0.93 | HRH1 (0.66) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL639360 | 0.91 | HRH1 (0.63) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL2877569 | 0.91 | HRH1 (0.63) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| SCHEMBL31540092 | 0.83 | HRH1 (0.43) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| SCHEMBL20400026 | 0.83 | HRH1 (0.43) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| SCHEMBL2110195 | 0.82 | CHRNB2 (0.66) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| SCHEMBL2266554 | 0.82 | CHRNB2 (0.66) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| SCHEMBL2264511 | 0.82 | CHRNB2 (0.66) | HRH1IKBKBCHUKCHRNB2CHRNA4 | |
| SCHEMBL3088213 | 0.77 | HRH1 (0.46) | HRH1IKBKBCHUKCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4665456-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | Arvinas Operations, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025072629-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | LRRK2, PINK1, PSMC1 | HRH1 1594/4885IKBKB 1536/4885CHUK 1282/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | HRH1 2843/4885IKBKB 782/4885CHUK 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.